-
Pre-clinical Development of a Parkinson's Disease Therapy Using a Glucagon-Like Peptide (GLP)-1 Receptor Agonist
… neurochemical, and histopathological deficits in multiple rodent models of PD. Exendin-4 has the potential to … A manuscript describing the effects of exendin-4 on multiple therapeutic endpoints, including neurobehavioral … in vivo, it has been shown to have robust efficacy in multiple rodent models of PD, and it is already an …
-
Warren D. Hirst, PhD
… α-synuclein antibody, which is in Phase 2 trials, using multiple modalities, from antibodies and antisense … grant review committees, and as an ad-hoc reviewer for multiple journals including Neuron and PNAS. Warren has received multiple grants in addition to serving as a reviewer and …
-
John Daniel O'Sullivan, MD
… in movement disorders research. He has led and coordinated multiple clinical trials in Parkinson's disease and has over … therapy in some patients. Dr. O'Sullivan currently oversees multiple research projects on non-motor symptoms in …
-
Martin E. Sanders, MD
… research, patient care, senior officer positions at multiple companies, venture capital partnership, and membership on multiple for-profit and non-profit boards. He is a …
-
Support for your Collaboration on Proof-of-concept clinical trial on the use of the 5-HT1A/1B Partial Agonist Eltoprazine for Treatment of L-DOPA-induced Dyskinesias. - Linked to Bjorklund CIA 2009
… fewer and fewer dopamine terminals survive, another neuron system kicks in: the serotonin neurons. The serotonin … transmitter,” but in a non-physiological manner. Studies in multiple pre-clinical models of the disease have shown that …
-
Novel Fumarate Esters as Neuroprotective Agents in Parkinson’s Disease
… immuno-modulatory and neuroprotective effects in cell-based systems, pre-clinical models of disease and clinical trials in multiple sclerosis and psoriasis patients. The biological …